medical device cleaning
Industry Analysis Medical & Healthcare

Global Cell and Gene Therapy Drug Delivery Devices Market to Reach $375.13 Thousand by 2030

The global cell and gene therapy drug delivery devices market is projected to reach $375.13 thousand by 2030,according to CRI’s new report. The study also highlights that the market is set to witness a CAGR of 16.61% during the period between 2020 and 2030.

Global Cell and Gene Therapy Drug Delivery Devices Market: Focus on Product Type, Commercialized Drug Delivery Devices, Country Data (16 Countries), and Competitive Landscape – Analysis and Forecast, 2020-2030

The comprehensive study of global cell and gene therapy drug delivery devices market extensively covers the following:

• Market numbers on micro-segments that are influencing the market
• Currently over 15 products present in the market
• Clinical trial data for over 30 clinical trials
• Pricing data for over 15 products
• Evaluation of over 20 brands
• Market share analysis
• End-user preference data
• Detailed global and regional market share analysis including the scrutiny of more than 15 countries
• Study of data of more than 20 companies

Besides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, and segmental analysis.

This report indicates that the increasing global geriatric population, prevalence of genetic disorders, the increased demand for gene therapeutics that not only cure the chronic conditions completely but also improve the quality of life of the patients are the major factors anticipated to contribute to the growth of the global cell and gene therapy drug delivery devices market.

The study highlights the various emerging opportunities, such as strong pipeline and drug approvals of cell and gene therapies, introduction of cell and gene therapy drug delivery devices, potential technologies in cell and gene therapy drug delivery devices market, original equipment manufacturers, clinical trial scenario, and approved cell and gene therapy drug delivery devices. Scope of cell and gene therapy drug delivery devices, the clinical trial landscape of cell and gene therapies in China, the U.S, and across the world, challenges in cell and gene therapy drug delivery devices, and massive scope for adoption of cell and gene therapy drug delivery devices in emerging nations that can be leveraged by players operating in the market.

Data from different segments of the market has been analyzed minutely to gain a holistic view of the market. These segments include market by product type, commercialized drugs, and regions. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.

To emphasize the dominance of the intravenous catheter segment of cell and gene therapy drug delivery devices market by product segment over other segments under the product category of cell and gene therapy drug delivery devices market in 2020 and 2030, “The reason for market growth and the dominance of intravenous catheter segment can be attributed to the increasing global usage of intravenous catheters to deliver drugs that are dosed frequently for fairly long periods of time and for specific disease conditions. For most of currently approved cell and gene therapies such as Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis, Zynteglo, and Tecartus intravenous catheter are used as its drug delivery device”

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 20 leading companies, market participants, and vendors. The key players profiled in the report include Amgen, Inc., Bausch & Lomb Incorporated, Becton, Dickinson and Company, Bluebird bio, Inc., Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd (ViroMed Co., Ltd), Human Stem Cell Institute, Kite Pharma, Inc., Kolon Tissue Gene, inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Renova Therapeutics, Spark Therapeutics, Inc., uniQure N.V., and Vericel Corporation.

The study also offers strategic recommendations that can help organizations in tracking various products, trends, and technologies that are changing the dynamics of the market. The recommendations also offer bespoke research services to help organizations meet their objectives.

Who should buy this report?

• Manufacturers of Cell and Gene Therapy Drug Delivery Devices
• Distributors of Cell and Gene Therapy Drug Delivery Devices
• Suppliers of Cell and Gene Therapy Drug Delivery Devices
• CROs of Cell and Gene Therapy Drug Delivery Devices
• Research and Academic Institutions

How can market intelligence on Cell and Gene Therapy Drug Delivery Devices add value to an organization’s decision-making process?

• Aids in product development
• Aids in analyzing the pipeline of products
• Helps in targeting a segment for launching a new product
• Offers go to market strategies for the different product categories
• Supports in diversifying the product portfolio based on unmet needs
• Helps in analyzing technological substitutes and compare the specification
• Helps in understanding the clinical trial landscape
• Helps to adjust the pricing of upcoming products
• Assists in exploring the newer applications
• Supports in analyzing the competitors’ funding scenario

Insightful Questions Covered to Enable Companies Take Strategic Decisions

• What are cell and gene therapy drug delivery devices?
• What is the list of commercialized cell and gene therapies available in the market?
• How did the cell and gene therapy drug delivery devices market evolve, and what is its scope in the future?
• What are the major market drivers, challenges and opportunities in the global cell and gene therapy drug delivery devices market?
• What are the key developmental strategies that are being implemented by the key players to sustain in this market?
• How did the emerging technology landscape of cell and gene therapy drug delivery devices look like?
• What will be the impact of COVID-19 on this market?
• What will be the impact of COVID-19 on cell and gene therapy drug delivery devices companies?
• What will be the impact of COVID-19 on supply chain of cell and gene therapy drug delivery devices market?
• What are the guidelines implemented by different government bodies to regulate the approval of cell and gene therapy drug delivery devices market?
• How the investments by government organizations will affect the global cell and gene therapy drug delivery devices market?
• What was the market size of the leading segments and sub-segments of the global cell and gene therapy drug delivery devices market in 2019?
• How will the industry evolve during the forecast period 2020- 2030?
• What will be the growth rate of the cell and gene therapy drug delivery devices market during the forecast period?
• How will each of the segments of the global cell and gene therapy drug delivery devices market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2030?
• Which product segment, and commercialized drug segment is expected to register the highest CAGR for the cell and gene therapy drug delivery devices market?
• What is the market size of cell and gene therapy drug delivery devices market in different countries of the world?
• Which geographical region will contribute to the highest sales of cell and gene therapy drug delivery devices market?
• What are the reimbursement scenario and regulatory structure for the cell and gene therapy drug delivery devices in different regions?
• What are the key strategies incorporated by the players of global cell and gene therapy drug delivery devices market, to sustain the competition and retain their supremacy?

    Request a sample

    Related posts

    Leave a Comment

    RSS
    Follow by Email